Plus Therapeutics, INC 10-Q quarterly reports

Plus Therapeutics reports Q1 2026 financial results, highlighting progress in clinical trials and diagnostic commercialization.

Plus Therapeutics reported a significant increase in cash and working capital, driven by recent financings, while advancing its radiotherapeutic pipeline and diagnostic platform, despite an increased net loss and ongoing Nasdaq bid price compliance challenges.

Plus Therapeutics reported a significant increase in cash and a shift to positive stockholders' equity in Q2 2025, driven by recent capital raises, despite ongoing operational losses and Nasdaq listing challenges.

Plus Therapeutics, a radiotherapeutics company, reported a significant increase in net loss for Q1 2025, alongside progress in its REYOBIQ clinical trials and ongoing efforts to address multiple Nasdaq listing deficiencies.

Plus Therapeutics reported its Q3 2024 financial results, highlighting ongoing clinical trials and efforts to regain Nasdaq compliance.

Plus Therapeutics reported its second quarter 2024 results, highlighting ongoing clinical trials and a recent private placement, while also addressing concerns about its financial position and Nasdaq listing compliance.

Plus Therapeutics reported a net loss of $3.26 million for the first quarter of 2024, while also securing $7.25 million in a private placement to bolster its financial position.